CD19 and neoplasm: Further, healthy donor Tn/mem-derived CD19-CAR and IL-13Rα2-CAR-T cell products exhibited improved anti-tumor activity in mice, as compared to Tcm-derived products (Supplementary Fig. 3b,c).